Effect of Tocilizumab on Fatigue and Bone Mineral Density in Patients with Rheumatoid Arthritis

被引：3

作者：

Abu-Shakra, Mahmoud ^{[1
,2
]}

Zisman, Devy ^{[3
,22
]}

Balbir-Gurman, Alexandra ^{[4
]}

Amital, Howard ^{[5
,6
,21
]}

Levy, Yair ^{[7
,21
]}

Langevitz, Pnina ^{[9
,21
]}

Tishler, Moshe ^{[10
,21
]}

Molad, Yair ^{[11
,21
]}

Aamar, Suhail ^{[12
]}

Roser, Itzhak ^{[13
,22
]}

Avshovich, Nina ^{[14
]}

Paran, Daphna ^{[15
,21
]}

Reitblat, Tatiana ^{[2
,16
,23
]}

Mader, Reuven ^{[17
,22
]}

Savin, Hillel ^{[8
]}

Friedman, Joshua ^{[18
]}

Lieberman, Nicky ^{[19
]}

Ehrlich, Sharon ^{[20
]}

机构：

[1] Soroka Univ Med Ctr, Rheumat Dis Unit, Beer Sheva, Israel

[2] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel

[3] Carmel Hosp, Rheumatol Unit, Haifa, Israel

[4] Technion Israel Inst Technol, Rappaport Fac Med, Rambam Med Ctr, Rheumatol Unit, Haifa, Israel

[5] Sheba Med Ctr, Dept Med B, Tel Hashomer, Israel

[6] Sheba Med Ctr, Zabludowicz Ctr Autoimmune Dis, Tel Hashomer, Israel

[7] Meir Med Ctr, Dept Internal Med E, Kefar Sava, Israel

[8] Meir Med Ctr, Rheumatol Unit, Kefar Sava, Israel

[9] Sheba Med Ctr, Dept Rheumatol, Tel Hashomer, Israel

[10] Assaf Harofeh Med Ctr, Dept Internal Med B, Zerifin, Israel

[11] Rabin Med Ctr, Rheumatol Unit, Beilinson Campus, Petah Tiqwa, Israel

[12] Hadassah Hebrew Univ Med Ctr, Rheumatol Serv, Jerusalem, Israel

[13] Bnai Zion Med Ctr, Rheumatol Unit, Haifa, Israel

[14] Hillel Yaffe Med Ctr, Dept Internal Med D, Hadera, Israel

[15] Tel Aviv Sourasky Med Ctr, Dept Rheumatol, Tel Aviv, Israel

[16] Barzilai Govt Hosp, Rheumatol Unit, Ashqelon, Israel

[17] Emek Med Ctr, Rheumatol Unit, Afula, Israel

[18] Kaplan Med Ctr, Rheumatol Unit, Rehovot, Israel

[19] Clalit Hlth Serv, Cent Off, Tel Aviv, Israel

[20] Roche Pharmaceut Israel Ltd, Hod Hasharon, Israel

[21] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[22] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel

[23] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel

来源：

ISRAEL MEDICAL ASSOCIATION JOURNAL | 2018年 / 20卷 / 04期

关键词：

tocilizumab; rheumatoid arthritis (RA); fatigue; bone mineral density (BMD); obesity; DISEASE-ACTIVITY; INTERLEUKIN-6; OSTEOPOROSIS; TUMOR;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Chronic fatigue is common among patients with rheumatoid arthritis (RA), affecting quality of life. Osteoporosis is a prevalent co-morbidity in RA patients. Objectives: To assess the effect of long-term treatment with tocilizumab on fatigue and bone mineral density (BMD) in RA patients with inadequate response to synthetic or biologic disease-modifying anti-rheumatic drugs. Methods: In this multicenter, open-label, non-controlled, single arm study, patients >= 18 years of age received intravenous tocilizumab 8 mg/kg every 4 weeks for 96 weeks. The primary outcome was the change in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score from baseline to weeks 24, 48, 72, and 96. BMD was assessed before and 96 weeks after treatment. Results: The study comprised 145 patients (mean age 53.4 +/- 13.4 years, 83.4% women). Of these, 88 (60.7%) completed the 2 year treatment period. The mean FACIT-Fatigue score improved consistently starting from week 4 and showed a statistically significant increase of 5.0 +/- 9.7, 6.8 +/- 10.5, 7.3 +/- 10.9, and 7.3 +/- 10.4 from baseline to weeks 24, 48, 72, and 96, respectively (P < 0.0001). Mean BMD of femoral neck and total spine remained stable. Disease activity, acute phase reactants, and composite efficacy measures decreased during the study, while hemoglobin levels increased. Adverse events and serious adverse events were as expected for the known and previously described data. Conclusions: Tocilizumab therapy for 2 years significantly and clinically decreased fatigue. BMD remained stable and no new safety issue was reported.

引用

页码：239 / 244

页数：6

共 22 条

[1]

BELZA BL, 1995, J RHEUMATOL, V22, P639

[2]

Cella D, 2005, J RHEUMATOL, V32, P811

[3] FACTORS WHICH CONTRIBUTE TO FATIGUE ASSOCIATED WITH RHEUMATOID-ARTHRITIS [J].